[HTML][HTML] GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.

T Gargett, LM Ebert, NTH Truong, PM Kollis… - … for Immunotherapy of …, 2022 - europepmc.org
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong, PM Kollis… - 2022 - digital.library.adelaide.edu.au
Background: Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

[PDF][PDF] GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and 1 clinically feasible therapy for glioblastoma 2

T Gargett - scholar.archive.org
All donors provided informed consent for the use of their de-identified tissue and blood 38
samples in this study. Use of human glioblastoma patient samples was approved by the 39 …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong… - Journal for …, 2022 - search.proquest.com
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong, PM Kollis… - bioRxiv, 2022 - biorxiv.org
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

[HTML][HTML] GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong, PM Kollis… - … for ImmunoTherapy of …, 2022 - jitc.bmj.com
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong… - Journal for …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T Gargett, LM Ebert, NTH Truong… - Journal for …, 2022 - researchnow.flinders.edu.au
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.

T Gargett, LM Ebert, NTH Truong, PM Kollis… - … for Immunotherapy of …, 2022 - europepmc.org
Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …